Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABEONA THERAPEUTICS INC.ABEO · Entity 5808 | Director | January 26, 2026 | January 27, 2026 |
| PRECISION BIOSCIENCES INCDTIL · Entity 6284 | Director · President and CEO | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABEONA THERAPEUTICS INC.
Report date January 26, 2026 · Filed January 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 217,779 |
Reported balance
After 2026-01-26 transaction · row 1
1 source rowRow 1 · 2026-01-26 · Grant · Acquired 37,313 · Balance 217,779 F1: All of the restricted stock will vest on January 26, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the restricted stock will vest on January 26, 2027.
PRECISION BIOSCIENCES INC
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 573,888 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 573,888 · Balance 573,888 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2: Award vests in three substantially equal annual installments beginning on February 18, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
F2: Award vests in three substantially equal annual installments beginning on February 18, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2023 Filed Mar 4, 2023 00:06 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 1,002 | $2.38 | $2,384.76 |
DisclosureSEC source: 0001493152-23-006716 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,709 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with vesting of restricted stock awards. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 800,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004608 · doc4.xml · derivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 20:11 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 850,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-055786 · doc4.xml · derivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,000 Underlying: Common Stock · 850,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Award represents a retention grant, which vests in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · derivative.expiration_date: Award represents a retention grant, which vests in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 11:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001209191-22-054587 · doc4.xml · derivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-10-23 F1 · security: The Reporting Person was granted stock options in accordance with the Reporting Person's employment agreement with the Issuer. F2 · derivative.exercise_date: The option vests as to 25% of the underlying shares on October 15, 2023 and thereafter in twelve substantially equal installments at the end of each three-month period over the 36 months following such date, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 20:13 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 11,006 | $1.32 | $14,527.92 |
DisclosureSEC source: 0001209191-22-053956 · doc4.xml · nonDerivative · entry 2 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,202 F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. Read SEC document |
| October 15, 2022 Filed Oct 18, 2022 20:13 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 24,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-053956 · doc4.xml · derivative · entry 3 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,208 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On October 15, 2021 the Reporting Person was granted RSUs, which vested on October 15, 2022. F4 · derivative.expiration_date: On October 15, 2021 the Reporting Person was granted RSUs, which vested on October 15, 2022. Read SEC document |
| October 15, 2022 Filed Oct 18, 2022 20:13 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 24,208 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-053956 · doc4.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting and settlement of Restricted Stock Units ("RSUs") on October 15, 2022. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 20:36 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 13,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-027048 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,711 F1 · shares: All of the restricted stock will vest on September 26, 2023. F2 · balance_after: On July 1, 2022, the issuer effectuated a 1-for-25 reverse stock split. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 21:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 307,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-020793 · doc4.xml · derivative · entry 2 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,544 Underlying: Common Stock · 307,544 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F3 · derivative.exercise_date: The RSUs shall vest in three substantially equal annual installments beginning on March 21, 2023, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F3 · derivative.expiration_date: The RSUs shall vest in three substantially equal annual installments beginning on March 21, 2023, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 21:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantEmployee Stock Option (Right to Buy) · Derivative | 482,771 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001209191-22-020793 · doc4.xml · derivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 482,771 Underlying: Common Stock · 482,771 shares Expires 2032-03-20 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on March 21, 2023 and thereafter in twelve substantially equal installments at the end of each three-month period over the 36 months following such date, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 20:09 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 24,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060890 · doc4.xml · derivative · entry 2 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,208 Underlying: Common Stock · 24,208 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F3 · derivative.exercise_date: The RSUs shall vest on October 15, 2022, subject to the Reporting Person's continued service to the Company through the vesting date. F3 · derivative.expiration_date: The RSUs shall vest on October 15, 2022, subject to the Reporting Person's continued service to the Company through the vesting date. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 20:09 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantEmployee Stock Option (Right to Buy) · Derivative | 850,000 | $0.00 Strike: $9.79 | $0.00 |
DisclosureSEC source: 0001209191-21-060890 · doc4.xml · derivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,000 Underlying: Common Stock · 850,000 shares Expires 2031-10-14 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on October 15, 2022 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 20:06 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon stock | 45,409 | $1.09 | $49,382.29 |
DisclosureSEC source: 0001493152-21-024499 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 604,637 F1 · kind: The sales reported in this Form 4 were to cover tax obligations associated with vested restricted stock awards and were effected pursuant to a Rule 10b5-1 trading plan adopted by Michael Amoroso on February 24, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.08 to $1.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 23:12 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon stock | 45,409 | $1.87 | $84,919.37 |
DisclosureSEC source: 0001493152-21-007902 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,046 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Michael Amoroso on February 24, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.805 to $1.945, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 20:08 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001493152-21-006622 · ownership.xml · derivative · entry 2 Amoroso Michael · CIK 0001830874 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-03-19 F2 · derivative.exercise_date: The options will vest 25% on March 19, 2022, and in 36 equal monthly installments thereafter. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 20:08 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-006622 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 695,455 F1 · shares: The restricted stock will vest 25% on each of March 19, 2022 and in 12 quarterly installments thereafter. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $2.34 | $0.00 |
DisclosureSEC source: 0001493152-21-005275 · ownership.xml · derivative · entry 2 Amoroso Michael · CIK 0001830874 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2031-03-01 F2 · derivative.exercise_date: The options will vest 25% on March 1, 2022, and in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-005275 · ownership.xml · nonDerivative · entry 1 Amoroso Michael · CIK 0001830874 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,455 F1 · shares: The restricted stock will vest 25% on each of March 1, 2022, March 1, 2023, March 1, 2024 and March 1, 2025. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Disposition to issuerStock Option (right to buy) · Derivative | 250,000 | Not disclosed Strike: $3.35 | Not disclosed |
DisclosureSEC source: 0001493152-20-022152 · ownership.xml · derivative · entry 2 Amoroso Michael · CIK 0001830874 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2030-11-02 F2 · price: The options granted on July 9, 2020 have been modified to reflect a lower exercise price. F1 · derivative.exercise_date: The options vest 25% on July 9, 2021, and in 36 equal monthly installments thereafter. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 250,000 | Not disclosed Strike: $1.15 | Not disclosed |
DisclosureSEC source: 0001493152-20-022152 · ownership.xml · derivative · entry 1 Amoroso Michael · CIK 0001830874 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-11-02 F2 · price: The options granted on July 9, 2020 have been modified to reflect a lower exercise price. F1 · derivative.exercise_date: The options vest 25% on July 9, 2021, and in 36 equal monthly installments thereafter. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:12 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001641172-20-000031 · ownership.xml · derivative · entry 1 Amoroso Michael · CIK 0001830874 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-11-02 F1 · derivative.exercise_date: The options will vest 25% on November 2, 2021, and in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.